Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537444 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
A Phase 2 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02537444 is a Phase 2 study that has completed, run by Acerta Pharma. The registered enrollment target is 78 participants.
The verdict
NCT02537444, a Phase 2 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Interventions
- DRUG Acalabrutinib
- DRUG acalabrutinib and pembrolizumab combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537444
The ClinicalTrials.gov registry entry for NCT02537444 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acalabrutinib is the first listed.
NCT02537444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02537444 about?
NCT02537444 is a clinical study titled "Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)". To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
What is the current status of trial NCT02537444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2015-11. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02537444?
The interventions under investigation include: Acalabrutinib (DRUG), acalabrutinib and pembrolizumab combination (DRUG).
Who is sponsoring clinical trial NCT02537444?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.